Context

MedinCell is a phase III pharma company developing a portfolio of long-acting injectable products in various therapeutic areas.

Its BEPO® technology is a polymer-based formulation ensuring controlled release of an API over a targeted period of days, weeks or months.

Potential to create a global schizophrenia franchise in partnership with TEVA : currently conducting phase III trial for a 2-month risperidone, the most advanced drug candidate.

First non-opioid intra articular pain and inflammation treatment post orthopedic surgery in phase II.

Ongoing R&D programs in: contraception with the Bill & Melinda Gates Foundation and in CNS with multiple indications.

The Company’s objective is to file at least one new IND every year.

IPO proceeds will be used to accelerate pipeline expansion and to further invest in the proprietary technology platform.

About MedinCell

MedinCell is a pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved adherence, i.e. adherence with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO® technology allows to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple depot of a few millimeters, fully bioresorbable. Based in Montpellier, MedinCell currently employs approximately 100 people representing over 25 different nationalities.

Discover MedinCell

Hervé Ronin

Investment Banking

Cosme Rosellini

Investment Banking

Romain Ellul

Investment Banking

Remi Negre

Investment Banking

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center